{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:33:41Z","timestamp":1790876021615,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["110897"],"award-info":[{"award-number":["110897"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Hypofractionated radiotherapy is the standard of care for adjuvant whole breast radiotherapy (RT). However, adoption has been slow. The indication for regional nodal irradiation has been expanded to include patients with 0\u20133 involved lymph nodes. We investigated the impact of the publication of the updated German S3 guidelines in 2017 on adoption of hypofractionation and enrollment of patients with lymph node involvement within a\u00a0randomized controlled phase\u00a0III trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the experimental arm of the HYPOSIB trial (NCT02474641), hypofractionated RT with simultaneous integrated boost (SIB) was used. In the standard arm, RT could be given as hypofractionated RT with sequential boost (HF<jats:sub>seq<\/jats:sub>), normofractionated RT with sequential boost (NF<jats:sub>seq<\/jats:sub>), or normofractionated RT with SIB (NF<jats:sub>SIB<\/jats:sub>). The cutoff date for the updated German S3 guidelines was December\u00a017, 2017. Temporal trends were analyzed by generalized linear regression models. Multiple logistic regression models were used to investigate the influence of time (prior to\/after guideline) and setting (university hospital\/other institutions) on the fractionation patterns.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Enrollment of patients with involved lymph nodes was low throughout the trial. Adoption of HF<jats:sub>seq<\/jats:sub> increased over time and when using the guideline publication date as cutoff. Results of the multiple logistic regressions showed an interaction between time and setting. Furthermore, the use of HF<jats:sub>seq<\/jats:sub> was significantly more common in university hospitals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The use of HF<jats:sub>seq<\/jats:sub> in the standard arm increased over the course of the HYPOSIB trial and after publication of the S3 guideline update. This was primarily driven by patients treated in university hospitals. Enrolment of patients with lymph node involvement was low throughout the trial.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-020-01730-9","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T13:35:09Z","timestamp":1608039309000},"page":"802-811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial"],"prefix":"10.1007","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-5416","authenticated-orcid":false,"given":"David","family":"Krug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Vonthein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Boicev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Dinges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Weinstrauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Olbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Illen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"He\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inke R.","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Dellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Dunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"1730_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1470-2045(06)70699-4","volume":"7","author":"JR Owen","year":"2006","unstructured":"Owen\u00a0JR, Ashton\u00a0A, Bliss\u00a0JM et al (2006) Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a\u00a0randomised trial. Lancet Oncol 7:467\u2013471. https:\/\/doi.org\/10.1016\/S1470-2045(06)70699-4","journal-title":"Lancet Oncol"},{"key":"1730_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","volume":"9","author":"SM Bentzen","year":"2008","unstructured":"START Trialists\u2019 Group, Bentzen\u00a0SM, Agrawal\u00a0RK et\u00a0al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a\u00a0randomised trial. Lancet Oncol 9:331\u2013341. https:\/\/doi.org\/10.1016\/S1470-2045(08)70077-9","journal-title":"Lancet Oncol"},{"key":"1730_CR3","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","volume":"371","author":"RK Agrawal","year":"2008","unstructured":"START Trialists\u2019 Group, Agrawal\u00a0RK, Aird\u00a0EGA et\u00a0al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a\u00a0randomised trial. Lancet 371:1098\u20131107. https:\/\/doi.org\/10.1016\/S0140-6736(08)60348-7","journal-title":"Lancet"},{"key":"1730_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/jnci\/94.15.1143","volume":"94","author":"T Whelan","year":"2002","unstructured":"Whelan\u00a0T, MacKenzie\u00a0R, Julian\u00a0J et al (2002) Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. JNCI J Natl Cancer Inst 94:1143\u20131150","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1730_CR5","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland\u00a0JS, Owen\u00a0JR, Dewar\u00a0JA et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14:1086\u20131094. https:\/\/doi.org\/10.1016\/S1470-2045(13)70386-3","journal-title":"Lancet Oncol"},{"key":"1730_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan\u00a0TJ, Pignol\u00a0J\u2011P, Levine\u00a0MN et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N\u00a0Engl J Med 362:513\u2013520. https:\/\/doi.org\/10.1056\/NEJMoa0906260","journal-title":"N Engl J Med"},{"key":"1730_CR7","volume-title":"Interdisziplin\u00e4re S3-Leitlinie f\u00fcr die Diagnostik, Therapie und Nachsorge des Mammakarzinoms","author":"Leitlinienprogramm Onkologie","year":"2012","unstructured":"Leitlinienprogramm Onkologie (2012) Interdisziplin\u00e4re S3-Leitlinie f\u00fcr die Diagnostik, Therapie und Nachsorge des Mammakarzinoms"},{"key":"1730_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.radonc.2013.12.006","volume":"110","author":"SN Badiyan","year":"2014","unstructured":"Badiyan\u00a0SN, Shah\u00a0C, Arthur\u00a0D et\u00a0al (2014) Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies. Radiother Oncol 110:39\u201344. https:\/\/doi.org\/10.1016\/j.radonc.2013.12.006","journal-title":"Radiother Oncol"},{"key":"1730_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1415369","volume":"373","author":"PM Poortmans","year":"2015","unstructured":"Poortmans\u00a0PM, Collette\u00a0S, Kirkove\u00a0C et\u00a0al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N\u00a0Engl J Med 373:317\u2013327. https:\/\/doi.org\/10.1056\/NEJMoa1415369","journal-title":"N Engl J Med"},{"key":"1730_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan\u00a0TJ, Olivotto\u00a0IA, Parulekar\u00a0WR et al (2015) Regional nodal irradiation in early-stage breast cancer. N\u00a0Engl J Med 373:307\u2013316. https:\/\/doi.org\/10.1056\/NEJMoa1415340","journal-title":"N Engl J Med"},{"key":"1730_CR11","unstructured":"\u00c4rzteblatt (2017) Aktualisierte S3-Leitlinie Brustkrebs erschienen. https:\/\/www.aerzteblatt.de\/nachrichten\/87128\/Aktualisierte-S3-Leitlinie-Brustkrebs-erschienen. Accessed: 19 September 2020"},{"key":"1730_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1055\/a-0646-4630","volume":"78","author":"A W\u00f6ckel","year":"2018","unstructured":"W\u00f6ckel\u00a0A, Festl\u00a0J, St\u00fcber\u00a0T et al (2018) Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032\/045OL, December 2017)\u2014part 2 with recommendations for the therapy of primary, recurrent and advanced breast cancer. Geburtshilfe Frauenheilkd 78:1056\u20131088. https:\/\/doi.org\/10.1055\/a-0646-4630","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"1730_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00066-014-0658-5","volume":"190","author":"K Dellas","year":"2014","unstructured":"Dellas\u00a0K, Vonthein\u00a0R, Zimmer\u00a0J et al (2014) Hypofractionation with simultaneous integrated boost for early breast cancer: results of the German multicenter phase II trial (ARO-2010-01). Strahlenther Onkol 190:646\u2013653. https:\/\/doi.org\/10.1007\/s00066-014-0658-5","journal-title":"Strahlenther Onkol"},{"key":"1730_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01689-7","author":"D Krug","year":"2020","unstructured":"Krug\u00a0D, Baumann\u00a0R, Krockenberger\u00a0K et al (2020) Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a\u00a0prospective trial. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-020-01689-7","journal-title":"Strahlenther Onkol"},{"key":"1730_CR15","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1001\/jama.2014.16616","volume":"312","author":"JE Bekelman","year":"2014","unstructured":"Bekelman\u00a0JE, Sylwestrzak\u00a0G, Barron\u00a0J et\u00a0al (2014) Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008\u20132013. JAMA 312:2542\u20132549. https:\/\/doi.org\/10.1001\/jama.2014.16616","journal-title":"JAMA"},{"key":"1730_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-017-4345-y","volume":"378","author":"TP Diwanji","year":"2017","unstructured":"Diwanji\u00a0TP, Molitoris\u00a0JK, Chhabra\u00a0AM et al (2017) Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a\u00a0National Cancer Database analysis. Breast Cancer Res Treat 378:1\u20139. https:\/\/doi.org\/10.1007\/s10549-017-4345-y","journal-title":"Breast Cancer Res Treat"},{"key":"1730_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10549-017-4120-0","volume":"162","author":"Y Hasan","year":"2017","unstructured":"Hasan\u00a0Y, Waller\u00a0J, Yao\u00a0K et\u00a0al (2017) Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Res Treat 162:317\u2013328. https:\/\/doi.org\/10.1007\/s10549-017-4120-0","journal-title":"Breast Cancer Res Treat"},{"key":"1730_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/1754-9485.12897","volume":"9","author":"KYK Jung","year":"2019","unstructured":"Jung\u00a0KYK, Shadbolt\u00a0B, Rezo\u00a0A (2019) Temporal impact of the publication of guidelines and randomised evidence on the adoption of hypofractionated whole breast radiotherapy for early-stage breast cancer. J\u00a0Med Imaging Radiat Oncol 9:331\u2013338. https:\/\/doi.org\/10.1111\/1754-9485.12897","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1730_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.radonc.2020.10.008","volume":"155","author":"I Ratosa","year":"2020","unstructured":"Ratosa\u00a0I, Chiril\u0103\u00a0ME, Steinacher\u00a0M et\u00a0al (2020) Hypofractionated radiation therapy for breast cancer: preferences amongst radiation oncologists in Europe\u2014results from an international survey. Radiother Oncol 155:17\u201326. https:\/\/doi.org\/10.1016\/j.radonc.2020.10.008","journal-title":"Radiother Oncol"},{"key":"1730_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ijrobp.2020.04.042","volume":"107","author":"G Hildebrandt","year":"2020","unstructured":"Hildebrandt\u00a0G, Stachs\u00a0A, Gerber\u00a0B et al (2020) Central review of radiation therapy planning among patients with breast-conserving surgery: results from a\u00a0quality assurance process integrated into the INSEMA trial. Int J Radiat Oncol Biol Phys 107:683\u2013693. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.04.042","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1730_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.rpor.2020.07.003","volume":"25","author":"M Mayinger","year":"2020","unstructured":"Mayinger\u00a0M, Straube\u00a0C, Habermehl\u00a0D et al (2020) Hypo- vs. normofractionated radiation therapy in breast cancer: a patterns of care analysis in German speaking countries. Rep Pract Oncol Radiother 25:775\u2013779. https:\/\/doi.org\/10.1016\/j.rpor.2020.07.003","journal-title":"Rep Pract Oncol Radiother"},{"key":"1730_CR22","doi-asserted-by":"publisher","first-page":"CD003860","DOI":"10.1002\/14651858.CD003860.pub4","volume":"7","author":"BE Hickey","year":"2016","unstructured":"Hickey\u00a0BE, James\u00a0ML, Lehman\u00a0M et\u00a0al (2016) Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev 7:CD3860. https:\/\/doi.org\/10.1002\/14651858.CD003860.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"1730_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13014-015-0452-2","volume":"10","author":"MMOM Aly","year":"2015","unstructured":"Aly\u00a0MMOM, Glatting\u00a0G, Jahnke\u00a0L et\u00a0al (2015) Comparison of breast simultaneous integrated boost (SIB) radiotherapy techniques. Radiat Oncol 10:139. https:\/\/doi.org\/10.1186\/s13014-015-0452-2","journal-title":"Radiat Oncol"},{"key":"1730_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13014-016-0590-1","volume":"11","author":"MMOM Aly","year":"2016","unstructured":"Aly\u00a0MMOM, Abo-Madyan\u00a0Y, Jahnke\u00a0L et al (2016) Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH). Radiat Oncol 11:16. https:\/\/doi.org\/10.1186\/s13014-016-0590-1","journal-title":"Radiat Oncol"},{"key":"1730_CR25","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/s41598-019-39469-8","volume":"9","author":"D Pasquier","year":"2019","unstructured":"Pasquier\u00a0D, Le Tinier\u00a0F, Bennadji\u00a0R et al (2019) Intensity-modulated radiation therapy with simultaneous integrated boost for locally advanced breast cancer: a\u00a0prospective study on toxicity and quality of life. Sci Rep 9:2759. https:\/\/doi.org\/10.1038\/s41598-019-39469-8","journal-title":"Sci Rep"},{"key":"1730_CR26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.breast.2015.08.002","volume":"24","author":"H-H Lee","year":"2015","unstructured":"Lee\u00a0H\u2011H, Hou\u00a0M\u2011F, Chuang\u00a0H\u2011Y et al (2015) Intensity modulated radiotherapy with simultaneous integrated boost vs. conventional radiotherapy with sequential boost for breast cancer\u2014a preliminary result. Breast 24:656\u2013660. https:\/\/doi.org\/10.1016\/j.breast.2015.08.002","journal-title":"Breast"},{"key":"1730_CR27","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1016\/j.ijrobp.2012.01.050","volume":"83","author":"EJ Bantema-Joppe","year":"2012","unstructured":"Bantema-Joppe\u00a0EJ, Schilstra\u00a0C, de Bock\u00a0GH et al (2012) Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30\u00a0months\u2019 follow-up. Int J Radiat Oncol Biol Phys 83:e471\u2013e477. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.01.050","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1730_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.radonc.2013.08.037","volume":"108","author":"EJ Bantema-Joppe","year":"2013","unstructured":"Bantema-Joppe\u00a0EJ, Vredeveld\u00a0EJ, de Bock\u00a0GH et al (2013) Five year outcomes of hypofractionated simultaneous integrated boost irradiation in breast conserving therapy; patterns of recurrence. Radiother Oncol 108:269\u2013272. https:\/\/doi.org\/10.1016\/j.radonc.2013.08.037","journal-title":"Radiother Oncol"},{"key":"1730_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13014-020-01652-x","volume":"15","author":"D Krug","year":"2020","unstructured":"Krug\u00a0D, K\u00f6der\u00a0C, H\u00e4fner\u00a0MF et al (2020) Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. Radiat Oncol 15:235. https:\/\/doi.org\/10.1186\/s13014-020-01652-x","journal-title":"Radiat Oncol"},{"key":"1730_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000501000","volume":"14","author":"N Ditsch","year":"2019","unstructured":"Ditsch\u00a0N, Untch\u00a0M, Thill\u00a0M et\u00a0al (2019) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2019. Breast Care 14:224\u2013245. https:\/\/doi.org\/10.1159\/000501000","journal-title":"Breast Care"},{"key":"1730_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000500999","volume":"14","author":"M Thill","year":"2019","unstructured":"Thill\u00a0M, Jackisch\u00a0C, Janni\u00a0W et\u00a0al (2019) AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2019. Breast Care 14:247\u2013255. https:\/\/doi.org\/10.1159\/000500999","journal-title":"Breast Care"},{"key":"1730_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","volume":"8","author":"BD Smith","year":"2018","unstructured":"Smith\u00a0BD, Bellon\u00a0JR, Blitzblau\u00a0R et al (2018) Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 8:145\u2013152. https:\/\/doi.org\/10.1016\/j.prro.2018.01.012","journal-title":"Pract Radiat Oncol"},{"key":"1730_CR33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2015.63.6456","volume":"34","author":"LBJ Thorsen","year":"2016","unstructured":"Thorsen\u00a0LBJ, Offersen\u00a0BV, Dan\u00f8\u00a0H et al (2016) DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J\u00a0Clin Oncol 34:314\u2013320. https:\/\/doi.org\/10.1200\/JCO.2015.63.6456","journal-title":"J Clin Oncol"},{"key":"1730_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00066-019-01537-3","volume":"196","author":"KJ Borm","year":"2020","unstructured":"Borm\u00a0KJ, Kessel\u00a0K, Devecka\u00a0M et al (2020) Variability in lymph node irradiation in patients with breast cancer-results from a\u00a0multi-center survey in German-speaking countries. Strahlenther Onkol 196:15\u201322. https:\/\/doi.org\/10.1007\/s00066-019-01537-3","journal-title":"Strahlenther Onkol"},{"key":"1730_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano\u00a0AE, Hunt\u00a0KK, Ballman\u00a0KV et\u00a0al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a\u00a0randomized clinical trial. JAMA 305:569\u2013575. https:\/\/doi.org\/10.1001\/jama.2011.90","journal-title":"JAMA"},{"key":"1730_CR36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00066-020-01636-6","volume":"196","author":"KJ Borm","year":"2020","unstructured":"Borm\u00a0KJ, Oechsner\u00a0M, D\u00fcsberg\u00a0M et\u00a0al (2020) Effect of hypofractionation on the incidental axilla dose during tangential field radiotherapy in breast cancer. Strahlenther Onkol 196:771\u2013778. https:\/\/doi.org\/10.1007\/s00066-020-01636-6","journal-title":"Strahlenther Onkol"},{"key":"1730_CR37","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00066-018-1350-y","volume":"337","author":"M Pazos","year":"2018","unstructured":"Pazos\u00a0M, Fiorentino\u00a0A, Gaasch\u00a0A et al (2018) Dose variability in different lymph node levels during locoregional breast cancer irradiation: the impact of deep-inspiration breath hold. Strahlenther Onkol 337:949\u2013948. https:\/\/doi.org\/10.1007\/s00066-018-1350-y","journal-title":"Strahlenther Onkol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-020-01730-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T16:00:04Z","timestamp":1631894404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-020-01730-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1730"],"URL":"https:\/\/doi.org\/10.1007\/s00066-020-01730-9","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]},"assertion":[{"value":"26 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"D.\u00a0Krug has received honoraria from Merck Sharp & Dome, outside of the submitted work. J.\u00a0H\u00f6rner-Rieber\u00a0received speaker fees and travel reimbursement from ViewRay Inc, as well as travel reimbursement form IntraOP Medical and Elekta Instrument AB outside the submitted work. R.\u00a0Vonthein, A.\u00a0Schreiber, A.D.\u00a0Boicev, J.\u00a0Zimmer, R.\u00a0Laubach, N.\u00a0Weidner, S.\u00a0Dinges, M.\u00a0Hipp, R.\u00a0Schneider, E.\u00a0Weinstrauch, T.\u00a0Martin, D.\u00a0Olbrich, A.\u00a0Illen, N.\u00a0He\u00dfler, I.R.\u00a0K\u00f6nig, K.\u00a0Dellas, and J.\u00a0Dunst declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Before start of enrollment, the trial protocol was approved by the leading ethics committee at the University of L\u00fcbeck (ID 12-163) and the respective ethics committee responsible for the individual participating sites. Written informed consent was provided by every patient before enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}